海创药业业绩快报：2025年度归母净利润亏损1.37亿元

Core Insights - The company reported a significant increase in revenue for the fiscal year 2025, achieving 20.67 million yuan, which represents a year-on-year growth of 5535.71% [1] - Despite the revenue growth, the company recorded a net loss attributable to shareholders of 137 million yuan, an improvement from a net loss of 199 million yuan in the same period last year [1] - The primary driver for the revenue increase was the approval and subsequent sales of the company's first Class 1 new drug, Deuteroenzalutamide soft capsules (Project No: HC-1119), which was approved for sale in May 2025 [1]